Issue Date: April 6, 2009
Solvay Mulls Options For Drug Business
Solvay is holding discussions with third parties as it analyzes options for its pharmaceutical business. The business had sales last year of almost $3.6 billion, about 28% of Solvay's total sales. After AkzoNobel's 2007 sale of its drug business to Schering-Plough, Solvay is one of the last big European companies with businesses that span pharmaceuticals, chemicals, and plastics.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society